These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 20310016)

  • 1. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
    Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
    Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with the loss of response to infliximab in patients with Crohn's disease.
    Sono K; Yamada A; Yoshimatsu Y; Takada N; Suzuki Y
    Cytokine; 2012 Aug; 59(2):410-6. PubMed ID: 22633084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
    Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
    Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.
    Oh EH; Ko DH; Seo H; Chang K; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    World J Gastroenterol; 2017 Feb; 23(8):1489-1496. PubMed ID: 28293096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C
    Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.
    Dreesen E; Van Stappen T; Ballet V; Peeters M; Compernolle G; Tops S; Van Steen K; Van Assche G; Ferrante M; Vermeire S; Gils A
    Aliment Pharmacol Ther; 2018 Feb; 47(3):346-355. PubMed ID: 29226370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
    Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
    Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
    Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
    J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.
    Levesque BG; Greenberg GR; Zou G; Sandborn WJ; Singh S; Hauenstein S; Ohrmund L; Wong CJ; Stitt LW; Shackelton LM; King D; Lockton S; Ducharme J; Feagan BG
    Aliment Pharmacol Ther; 2014 May; 39(10):1126-35. PubMed ID: 24689499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
    Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
    Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT.
    Teixeira FV; Sassaki LY; Saad-Hossne R; Baima JP; Magro DO; Coy CSR; Kotze PG
    Arq Gastroenterol; 2018; 55(2):192-197. PubMed ID: 30043873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
    Vermeire S; Noman M; Van Assche G; Baert F; D'Haens G; Rutgeerts P
    Gut; 2007 Sep; 56(9):1226-31. PubMed ID: 17229796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Hofmekler T; Bertha M; McCracken C; Martineau B; McKinnon E; Schoen BT; McElhanon BO; Tenjarla G; Kugathasan S; Sauer CG
    J Pediatr Gastroenterol Nutr; 2017 Apr; 64(4):580-585. PubMed ID: 28079601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease.
    Gomes LEM; da Silva FAR; Pascoal LB; Ricci RL; Nogueira G; Camargo MG; Lourdes Setsuko Ayrizono M; Fagundes JJ; Leal RF
    Clinics (Sao Paulo); 2019 Apr; 74():e824. PubMed ID: 30994711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum infliximab concentrations in pediatric inflammatory bowel disease.
    Hämäläinen A; Sipponen T; Kolho KL
    Scand J Gastroenterol; 2013 Jan; 48(1):35-41. PubMed ID: 23148710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.